# Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

> **NCT00773747** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 637 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Vorinostat
- **DRUG:** bortezomib
- **DRUG:** placebo to vorinostat

## Key facts

- **NCT ID:** NCT00773747
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-01
- **Primary completion:** 2011-09-08
- **Final completion:** 2015-06-30
- **Target enrollment:** 637 (ACTUAL)
- **Last updated:** 2021-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00773747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00773747, "Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00773747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*